142 related articles for article (PubMed ID: 1708923)
1. Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Int; 1991; 46(1):6-8. PubMed ID: 1708923
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
5. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
Grob BM; Schellhammer PF; Brassil DN; Wright GL
Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238
[TBL] [Abstract][Full Text] [Related]
6. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
7. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8.
Ljung G; Norberg M; Holmberg L; Busch C; Nilsson S
Prostate; 1997 May; 31(2):91-7. PubMed ID: 9140121
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers.
Seamonds B; Yang N; Anderson K; Whitaker B; Shaw LM; Bollinger JR
Urology; 1986 Dec; 28(6):472-9. PubMed ID: 2431533
[TBL] [Abstract][Full Text] [Related]
11. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.
Landmann C; Hunig R
Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):1073-6. PubMed ID: 2478510
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
[TBL] [Abstract][Full Text] [Related]
13. Effect of external beam radiation therapy on serum prostate-specific antigen.
Chodak GW; Neumann J; Blix G; Sutton H; Farah R
Urology; 1990 Apr; 35(4):288-94. PubMed ID: 1690936
[TBL] [Abstract][Full Text] [Related]
14. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen after post-prostatectomy radiotherapy.
Kaplan ID; Bagshaw MA
Urology; 1992 May; 39(5):401-6. PubMed ID: 1374576
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Russell KJ; Dunatov C; Hafermann MD; Griffeth JT; Polissar L; Pelton J; Cole SB; Taylor EW; Wiens LW; Koh WJ
J Urol; 1991 Oct; 146(4):1046-52. PubMed ID: 1716696
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; FĂ©lix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
20. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line.
Henttu P; Vihko P
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):349-60. PubMed ID: 1373297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]